Gold bars to be exempt from tariffs, White House clarifies
FREMONT, Calif. - Personalis, Inc. (NASDAQ:PSNL), whose stock has delivered an impressive 360% return over the past year according to InvestingPro data, and Tempus AI, Inc. (NASDAQ:TEM) have expanded and extended their strategic collaboration for cancer recurrence detection technology through 2029, according to a press release statement.
The companies have added colorectal cancer (CRC) to their existing exclusive commercialization agreement, which already covered breast cancer, lung cancer, and solid tumor immunotherapy monitoring. The collaboration focuses on bringing Personalis’ NeXT Personal minimal residual disease (MRD) test to market across these four cancer types. With a strong financial health score and current ratio of 6.91, Personalis appears well-positioned to support this expansion.
The expanded agreement extends the initial collaboration term to November 2029, with Tempus maintaining exclusivity for all four indications through 2028. This development follows the presentation of interim analysis results from the VICTORI study at the 2025 American Association for Cancer Research Annual Meeting, which demonstrated the performance of NeXT Personal in detecting early signs of colorectal cancer recurrence.
Colorectal cancer affects over 150,000 new patients annually in the United States, with many experiencing recurrence after initial treatment.
"Every day, thousands of cancer survivors live with the uncertainty of whether their cancer will return," said Chris Hall, CEO of Personalis. "By expanding our collaboration with Tempus to include CRC, we’re bringing peace of mind to more patients while building the evidence needed for broad reimbursement coverage for multiple indications."
The collaboration aims to leverage Personalis’ MRD testing platform with Tempus’ market reach to more than 50% of U.S. oncologists, potentially allowing for earlier detection of cancer recurrence and more personalized patient management approaches.
The companies’ NeXT Personal test is designed to detect minimal residual disease and cancer recurrence at early timepoints, which could enable more timely intervention for cancer patients. Personalis has demonstrated solid revenue growth of 15.57% over the last twelve months, reflecting the company’s expanding market presence. For deeper insights into Personalis’s financial metrics and growth potential, investors can access the comprehensive Pro Research Report available on InvestingPro, which includes detailed analysis of over 30 key financial indicators and future growth projections.
In other recent news, Personalis Inc. reported its first-quarter 2025 earnings, surpassing analyst expectations with an earnings per share of -$0.18, compared to the forecast of -$0.25. The company also exceeded revenue forecasts, posting $20.6 million against the expected $17.5 million. H.C. Wainwright maintained a Buy rating on Personalis and raised the price target to $9.00 from $8.00, reflecting confidence in the company’s growth trajectory. The firm’s financial projections now extend to 2032, with expected revenues growing from $85.9 million in 2025 to $654.2 million by 2032.
Personalis experienced significant growth in its NeXT Personal molecular tests, with a 52% increase in the first quarter of 2025, indicating strong demand. The company’s minimal residual disease (MRD) platform within the biopharma business segment is gaining traction, with increasing adoption by both existing and new customers. Additionally, Personalis revealed that its NeXT Personal circulating tumor DNA (ctDNA) blood test could predict cervical cancer progression up to 16 months earlier than imaging methods. This development was presented at the American Society for Clinical Oncology 2025 Annual Meeting.
The company’s strategic focus on the MRD market is underscored by its recent launch of the NextPersonal MRD test and a partnership with Tempus for sales and marketing. Personalis’ Chief Medical Officer emphasized the significance of these results for cervical cancer management, highlighting the test’s potential in guiding treatment decisions. The company continues to focus on innovation and expanding its clinical evidence across various cancer indications, positioning itself for future growth.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.